Itopride - AbbVie
Alternative Names: Ganaton; HSR 803; ItaxLatest Information Update: 20 Apr 2026
At a glance
- Originator Abbott Japan
- Developer Abbott Japan; AbbVie; Astellas Pharma; Axcan Pharma
- Class Antiulcers; Benzamides; Benzyl compounds; Gastrokinetics; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastritis; Gastrointestinal disorders
- Phase III Non-ulcer dyspepsia
- Discontinued Diabetic gastroparesis; Postoperative ileus
Most Recent Events
- 28 Feb 2025 Abbott completes a phase III trial in Non-ulcer dyspepsia in Armenia, Malaysia, Philippines, Thailand, Vietnam (PO) (NCT06217393)
- 28 Feb 2024 Phase-III clinical trials in Non-ulcer dyspepsia in Philippines, Thailand, Vietnam (PO) (NCT06217393)
- 28 Feb 2024 Phase-III clinical trials in Non-ulcer dyspepsia in Armenia, Malaysia (PO, Controlled release) (NCT06217393)